• Something wrong with this record ?

Revaskularizace nemá u pacientů se stenózou renální tepny příznivý vliv na kontrolu krevního tlaku, renální funkci ani kardiovaskulární prognózu
[Revascularization versus medical therapy for renal-artery stenosis]

. 2009 ; 7 (6) : 91-92.

Language Czech Country Czech Republic

Document type Comparative Study, Multicenter Study

Percutaneous revascularization of the renal arteries improves patency in atherosclerotic renovascular disease, yet evidence of a clinical benefit is limited. METHODS: In a randomized, unblinded trial, we assigned 806 patients with atherosclerotic renovascular disease either to undergo revascularization in addition to receiving medical therapy or to receive medical therapy alone. The primary outcome was renal function, as measured by the reciprocal of the serum creatinine level (a measure that has a linear relationship with creatinine clearance). Secondary outcomes were blood pressure, the time to renal and major cardiovascular events, and mortality. The median follow-up was 34 months. RESULTS: During a 5-year period, the rate of progression of renal impairment (as shown by the slope of the reciprocal of the serum creatinine level) was -0.07x10(-3) liters per micromole per year in the revascularization group, as compared with -0.13x10(-3) liters per micromole per year in the medical-therapy group, a difference favoring revascularization of 0.06x10(-3) liters per micromole per year (95% confidence interval [CI], -0.002 to 0.13; P=0.06). Over the same time, the mean serum creatinine level was 1.6 micromol per liter (95% CI, -8.4 to 5.2 [0.02 mg per deciliter; 95% CI, -0.10 to 0.06]) lower in the revascularization group than in the medical-therapy group. There was no significant between-group difference in systolic blood pressure; the decrease in diastolic blood pressure was smaller in the revascularization group than in the medical-therapy group. The two study groups had similar rates of renal events (hazard ratio in the revascularization group, 0.97; 95% CI, 0.67 to 1.40; P=0.88), major cardiovascular events (hazard ratio, 0.94; 95% CI, 0.75 to 1.19; P=0.61), and death (hazard ratio, 0.90; 95% CI, 0.69 to 1.18; P=0.46). Serious complications associated with revascularization occurred in 23 patients, including 2 deaths and 3 amputations of toes or limbs. CONCLUSIONS: We found substantial risks but no evidence of a worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease. (Current Controlled Trials number, ISRCTN59586944.) 2009 Massachusetts Medical Society

Revascularization versus medical therapy for renal-artery stenosis

The ASTRAL Investigators

000      
00000naa 2200000 a 4500
001      
bmc10004694
003      
CZ-PrNML
005      
20111210160525.0
008      
100224s2009 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
245    10
$a Revaskularizace nemá u pacientů se stenózou renální tepny příznivý vliv na kontrolu krevního tlaku, renální funkci ani kardiovaskulární prognózu.
246    11
$a Revascularization versus medical therapy for renal-artery stenosis
500    __
$a The ASTRAL Investigators
520    9_
$a Percutaneous revascularization of the renal arteries improves patency in atherosclerotic renovascular disease, yet evidence of a clinical benefit is limited. METHODS: In a randomized, unblinded trial, we assigned 806 patients with atherosclerotic renovascular disease either to undergo revascularization in addition to receiving medical therapy or to receive medical therapy alone. The primary outcome was renal function, as measured by the reciprocal of the serum creatinine level (a measure that has a linear relationship with creatinine clearance). Secondary outcomes were blood pressure, the time to renal and major cardiovascular events, and mortality. The median follow-up was 34 months. RESULTS: During a 5-year period, the rate of progression of renal impairment (as shown by the slope of the reciprocal of the serum creatinine level) was -0.07x10(-3) liters per micromole per year in the revascularization group, as compared with -0.13x10(-3) liters per micromole per year in the medical-therapy group, a difference favoring revascularization of 0.06x10(-3) liters per micromole per year (95% confidence interval [CI], -0.002 to 0.13; P=0.06). Over the same time, the mean serum creatinine level was 1.6 micromol per liter (95% CI, -8.4 to 5.2 [0.02 mg per deciliter; 95% CI, -0.10 to 0.06]) lower in the revascularization group than in the medical-therapy group. There was no significant between-group difference in systolic blood pressure; the decrease in diastolic blood pressure was smaller in the revascularization group than in the medical-therapy group. The two study groups had similar rates of renal events (hazard ratio in the revascularization group, 0.97; 95% CI, 0.67 to 1.40; P=0.88), major cardiovascular events (hazard ratio, 0.94; 95% CI, 0.75 to 1.19; P=0.61), and death (hazard ratio, 0.90; 95% CI, 0.69 to 1.18; P=0.46). Serious complications associated with revascularization occurred in 23 patients, including 2 deaths and 3 amputations of toes or limbs. CONCLUSIONS: We found substantial risks but no evidence of a worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease. (Current Controlled Trials number, ISRCTN59586944.) 2009 Massachusetts Medical Society
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a financování organizované $7 D005381
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a balónková angioplastika $x škodlivé účinky $7 D000800
650    _2
$a antihypertenziva $x terapeutické užití $7 D000959
650    _2
$a krevní tlak $7 D001794
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x terapeutické užití $7 D019161
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
650    _2
$a obstrukce renální arterie $7 D012078
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a multicentrická studie $7 D016448
773    0_
$w MED00012709 $t Postgraduální nefrologie $g Roč. 7, č. 6 (2009), s. 91-92 $x 1214-178X
787    18
$w bmc10004695 $i Recenze v: $t Komentář [k článku Revaskularizace nemá u pacientů se stenózou renální tepny příznivý vliv na kontrolu krevního tlaku, renální funkci ani kardiovaskulární prognózu]
856    41
$u https://www.postgradualninefrologie.cz/download/format/pdf/id/180/ $y plný text volně přístupný
910    __
$a ABA008 $b B 2318 $c 893 $y 8
990    __
$a 20100223151344 $b ABA008
991    __
$a 20100503101442 $b ABA008
999    __
$a ok $b bmc $g 714116 $s 577064
BAS    __
$a 3
BMC    __
$a 2009 $b 7 $c 6 $d 91-92 $i 1214-178X $m Postgraduální nefrologie $x MED00012709
LZP    __
$a 2010-03/mkme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...